BioMarin Pharmaceuticals (BMRN)

• Market cap: $13B
• 1 day: -0.70%
• 5 days: 5.52%
• 1 month: 9.15%
• 3 months: 7.57%
• 6 months: -26.27%
• Year to date: 2.65%
• 1 year: -22.92%
• 5 years: -28.28%
• 10 years: -36.71%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

75% more funds holding in top 10

Funds holding in top 10: 4 [Q3] → 7 (+3) [Q4]

11% more repeat investments, than reductions

Existing positions increased: 197 | Existing positions reduced: 177

1.48% more ownership

Funds ownership: 94.41% [Q3] → 95.9% (+1.48%) [Q4]

10% more call options, than puts

Call options by funds: $141M | Put options by funds: $128M

2% less first-time investments, than exits

New positions opened: 85 | Existing positions closed: 87

5% less capital invested

Capital invested by funds: $12.6B [Q3] → $12B (-$618M) [Q4]

4% less funds holding

Funds holding: 543 [Q3] → 519 (-24) [Q4]

Research analyst outlook

7 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $70 3% upside
• Avg. target: $95 39% upside
• High target: $126 85% upside

7 analyst ratings

• positive: 4 57%
• neutral: 3 43%
• negative: 0 0%

Scotiabank George Farmer 29% 1-year accuracy 7 / 24 met price target	17% upside $80	Sector Perform Maintained	20 Feb 2025
Citigroup David Lebovitz 69% 1-year accuracy 11 / 16 met price target	20% upside $82	Neutral Maintained	20 Feb 2025
RBC Capital Luca Issi 21% 1-year accuracy 12 / 56 met price target	3% upside $70	Sector Perform Reiterated	20 Feb 2025
Cantor Fitzgerald Olivia Brayer 39% 1-year accuracy 9 / 23 met price target	32% upside $90	Overweight Reiterated	20 Feb 2025
UBS Eliana Merle 35% 1-year accuracy 8 / 23 met price target	66% upside $113	Buy Maintained	20 Feb 2025